NCT04152473View on ClinicalTrials.gov

Safety and Tolerability of Oral Proglumide for NASH

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

September 9, 2022

Conditions
Nonalcoholic Steatohepatitis
Interventions
DRUG

Proglumide

oral CCK receptor antagonist

Trial Locations (2)

20007

Georgetown University, Washington D.C.

20422

Washington DC Veterans Affairs Medical Center, Washington D.C.

All Listed Sponsors
lead

Georgetown University

OTHER

NCT04152473 - Safety and Tolerability of Oral Proglumide for NASH | Biotech Hunter | Biotech Hunter